サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1378733

片頭痛治療薬市場レポート：治療タイプ、薬剤タイプ、投与経路、流通チャネル、地域別、2023-2028年

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 140 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
片頭痛治療薬市場レポート：治療タイプ、薬剤タイプ、投与経路、流通チャネル、地域別、2023-2028年
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界の片頭痛治療薬の市場規模は、2022年に40億米ドルに達しました。今後、IMARC Groupは、2022年から2028年の成長率（CAGR）は5.1％で、市場は2028年までに54億米ドルに達すると予測しています。

片頭痛は、額、側頭部、目の周囲に片側性またはズキズキする痛みを引き起こす神経疾患です。痛みは、吐き気、嘔吐、羞明、蓄音症などの自律神経症状を伴うことが多いです。片頭痛は一般に、患者の病歴や症状を調べるほか、血液検査、磁気共鳴画像装置（MRI）やコンピューター断層撮影装置（CT）検査を行うことで診断されます。現在、症状を和らげ、片頭痛発作の頻度や重症度を軽減するために、市販薬（OTC）や処方された注射薬が利用できます。これらの薬は、定期的に服用するか、発作時や慢性疼痛の増悪時に服用します。

片頭痛の有病率と診断数の大幅な増加は、市場の成長を後押しする重要な要因のひとつです。これとは別に、片頭痛治療薬に対する償還政策の改善、精密医薬品に対する需要の高まりも市場成長に寄与しています。さらに、片頭痛を治療するための電気神経刺激装置に対する需要の高まりや、カルシトニン遺伝子関連ペプチド（CGRP）モノクローナル抗体の導入など、後期開発段階にあり、より高い臨床的有効性を有する新クラスの薬剤の承認が期待されていることも、市場成長の原動力となっています。しかし、社会的な距離を置く規範により、片頭痛の臨床的な受診や手続きによる治療が減少していることが、市場成長に影響を与えています。

本レポートで扱う主な質問

  • 片頭痛治療薬の世界市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19が世界の片頭痛治療薬市場に与えた影響は？
  • 主要地域市場は？
  • 治療タイプ別の市場内訳は？
  • 薬剤タイプ別の市場内訳は？
  • 投与経路別の市場内訳は？
  • 流通チャネル別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主な促進要因と課題は何か？
  • 世界の片頭痛治療薬市場の構造と主要プレーヤーは？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 片頭痛治療薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • 頓挫治療
    • 市場動向
    • 市場予測
  • 予防治療
    • 市場動向
    • 市場予測

第7章 市場内訳：薬剤タイプ別

  • トリプタン製剤
    • 市場動向
    • 市場予測
  • 麦角アルカロイド類
    • 市場動向
    • 市場予測
  • 非ステロイド性抗炎症薬
    • 市場動向
    • 市場予測
  • アセチルコリン阻害剤/神経毒
    • 市場動向
    • 市場予測
  • ダイタン
    • 市場動向
    • 市場予測
  • CGRP mAbs
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：投与経路別

  • 経口剤
    • 市場動向
    • 市場予測
  • 注射剤
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：流通チャネル別

  • 病院内薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Allergan Plc（Abbvie Inc.）
    • Amgen Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc.（formerly Valeant Pharmaceuticals）
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • Endo International Plc
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Limited
図表

List of Figures

  • Figure 1: Global: Migraine Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Migraine Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Migraine Drugs Market: Breakup by Treatment Type (in %), 2022
  • Figure 4: Global: Migraine Drugs Market: Breakup by Drug Type (in %), 2022
  • Figure 5: Global: Migraine Drugs Market: Breakup by Route of Administration (in %), 2022
  • Figure 6: Global: Migraine Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Migraine Drugs Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Migraine Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 9: Global: Migraine Drugs (Abortive Treatment) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Migraine Drugs (Abortive Treatment) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Migraine Drugs (Preventive Treatment) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Migraine Drugs (Preventive Treatment) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Migraine Drugs (Triptans) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Migraine Drugs (Triptans) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Migraine Drugs (Ergot Alkaloids) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Migraine Drugs (Ergot Alkaloids) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Migraine Drugs (NSAIDs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Migraine Drugs (NSAIDs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Migraine Drugs (Ditans) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Migraine Drugs (Ditans) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Migraine Drugs (CGRP mAbs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Migraine Drugs (CGRP mAbs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Migraine Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Migraine Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Migraine Drugs (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Migraine Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Migraine Drugs (Injectable) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Migraine Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Migraine Drugs (Other Routes of Administration) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Migraine Drugs (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Migraine Drugs (Hospital-Based Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Migraine Drugs (Hospital-Based Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Global: Migraine Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Global: Migraine Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Global: Migraine Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Global: Migraine Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: North America: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: North America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: United States: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: United States: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Canada: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Canada: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Asia Pacific: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Asia Pacific: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: China: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: China: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Japan: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Japan: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: India: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: India: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: South Korea: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: South Korea: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: Australia: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: Australia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Indonesia: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Indonesia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Others: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Europe: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Europe: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Germany: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Germany: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: France: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: France: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: United Kingdom: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: United Kingdom: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Italy: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Italy: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Spain: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Spain: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Russia: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Russia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Others: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Latin America: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Latin America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Brazil: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: Brazil: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Mexico: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: Mexico: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Others: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 84: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Middle East and Africa: Migraine Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 86: Middle East and Africa: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Global: Migraine Drugs Industry: SWOT Analysis
  • Figure 88: Global: Migraine Drugs Industry: Value Chain Analysis
  • Figure 89: Global: Migraine Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Migraine Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Migraine Drugs Market Forecast: Breakup by Treatment Type (in Million US$), 2023-2028
  • Table 3: Global: Migraine Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 4: Global: Migraine Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 5: Global: Migraine Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 6: Global: Migraine Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Migraine Drugs Market Structure
  • Table 8: Global: Migraine Drugs Market: Key Players
目次
Product Code: SR112023A2543

Abstract

The global migraine drugs market size reached US$ 4.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2028, exhibiting a growth rate (CAGR) of 5.1% during 2022-2028.

Migraine is a neurological condition that causes unilateral or throbbing pain in the forehead, side of the head or around the eyes. The pain is often accompanied by autonomic symptoms, such as nausea, vomiting, photophobia and phonophobia. Migraine is generally diagnosed by examining the patient's medical history and symptoms, as well as by performing blood tests, and magnetic resonance imaging (MRI) and computerized tomography (CT) scans. At present, over the counter (OTC) medicines and prescribed injections are available to relieve the symptoms and reduce the frequency and severity of migraine attacks. These drugs are either taken regularly or during attacks or exacerbations of chronic pain.

A significant rise in the prevalence and diagnosis of migraine represents one of the key factors bolstering the market growth. Apart from this, the improvement in reimbursement policies for migraine medications, along with the escalating demand for precision medicines, is also contributing to the market growth. Furthermore, the growing demand for electrical nerve stimulating devices to treat migraine and the expected approval of new classes of drugs that are in late-stage pipeline and have higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are also driving the market growth. However, a decline in clinical visits and procedural treatment of migraines due to social distancing norms has impacted the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global migraine drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on treatment type, drug type, route of administration and distribution channel.

Breakup by Treatment Type:

Abortive Treatment

Preventive Treatment

Breakup by Drug Type:

Triptans

Ergot Alkaloids

NSAIDs

Acetylcholine Inhibitors/ Neurotoxins

Ditans

CGRP mAbs

Others

Breakup by Route of Administration:

Oral

Injectable

Others

Breakup by Distribution Channel:

Hospital-Based Pharmacies

Retail Pharmacies

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.

Key Questions Answered in This Report:

  • How has the global migraine drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global migraine drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global migraine drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Migraine Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Abortive Treatment
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Preventive Treatment
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Triptans
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ergot Alkaloids
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 NSAIDs
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Acetylcholine Inhibitors/ Neurotoxins
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Ditans
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 CGRP mAbs
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital-Based Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Allergan Plc (Abbvie Inc.)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Amgen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 AstraZeneca Plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Eisai Co. Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Eli Lilly and Company
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Endo International Plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 GlaxoSmithKline Plc
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Johnson & Johnson
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Merck & Co.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Novartis AG
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Pfizer Inc.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Sanofi SA
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis
    • 15.3.15 Teva Pharmaceutical Industries Limited
      • 15.3.15.1 Company Overview
      • 15.3.15.2 Product Portfolio
      • 15.3.15.3 Financials
      • 15.3.15.4 SWOT Analysis